Free tool
FAERS Monitor: Turalio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211810 or its brand name (Turalio, Pexidartinib Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
717
Serious
117
16% of reports
Hospitalization
53
Death reported
14
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue270
- fatigue251
- hair colour changes236
- nausea138
- pruritus113
- off label use106
- rash87
- therapy cessation81
- pain76
- headache72
- product dose omission in error69
- product use issue67
- diarrhoea66
- arthralgia65
- no adverse event56
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 37 |
| 2020 | 109 |
| 2021 | 131 |
| 2022 | 115 |
| 2023 | 120 |
| 2024 | 105 |
| 2025 | 61 |
| 2026 | 39 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,442 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hair colour changesSignal | 236 | 567.0 | 510.0 | 130,345 |
| product dose omission in errorSignal | 69 | 71.7 | 57.2 | 4,731 |
| therapy cessationSignal | 81 | 46.4 | 37.8 | 3,553 |
| product dose omission issueSignal | 270 | 27.0 | 24.5 | 6,812 |
| product use issueSignal | 67 | 10.5 | 8.3 | 569 |
| fatigueSignal | 251 | 9.5 | 8.6 | 1,963 |
| no adverse eventSignal | 56 | 9.1 | 7.1 | 397 |
| pruritusSignal | 113 | 8.6 | 7.3 | 768 |
| rashSignal | 87 | 5.9 | 4.8 | 353 |
| nauseaSignal | 138 | 5.1 | 4.4 | 470 |
| arthralgiaSignal | 65 | 4.6 | 3.6 | 182 |
| painSignal | 76 | 3.6 | 2.9 | 146 |
| off label useSignal | 106 | 3.6 | 3.0 | 200 |
| headacheSignal | 72 | 3.4 | 2.7 | 121 |
| diarrhoeaSignal | 66 | 3.0 | 2.4 | 89 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.